Search
Alfacalcidol
go.drugbank.com/drugs/DB01436ApprovedInvestigationalNutraceuticalThe pharmacological actions of alfacalcidol are prolonged than vitamin D because a negative feedback mechanism regulates the final activation step of vitamin D in the kidneys. … Alfacalcidol, or 1-alpha-hydroxycholecalciferol or 1-alpha-hydroxyvitamin D3, is a non-endogenous analogue of [vitamin D].
Products: ALFACALCIDOL 1A PHAR0.5UG, ALFACALCIDOL 1A PHAR0.25UGDipivefrin
go.drugbank.com/drugs/DB00449ApprovedWithdrawnDipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).
Categories: Sympathomimetics in Glaucoma TherapyAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalThis binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. … It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue
Atogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigational[A239094] The "gepants" family of drugs, including atogepant, are comparatively well-tolerated[A189207,L38739] and may provide a desirable treatment option for patients struggling with adverse reactions … [L38814] In December 2022, atogepant received Health Canada approval for the prevention of episodic migraine in adults.
Sipavibart
go.drugbank.com/drugs/DB21908ApprovedInvestigationalSipavibart is a recombinant human IgG1 monoclonal antibody that is long-acting. … [L53418] Sipavibart gained its first global approval in Japan in December 2024.[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025.
Sacubitril
go.drugbank.com/drugs/DB09292ApprovedInvestigationalSacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection … It was approved by the FDA after being given the status of priority review for on July 7, 2015.
Islatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigationaladults who are virologically suppressed on a stable antiretroviral regimen. … Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection.
Hydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigational[L14312]** Hydroxychloroquine was granted FDA approval on 18 April 1955.[L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546] … Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer.[A183047] Hydroxychloroquine is an aminoquinoline like [chloroquine].
Synonyms: 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline, 7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinolineCabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. … Cabergoline possesses potent agonist activity on dopamine D2 receptors.
Synonyms: (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexDihydralazine
go.drugbank.com/drugs/DB12945ApprovedWithdrawnDihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).
Categories: Arteriolar Smooth Muscle, Agents Acting On